Last reviewed 2026-05-15 · How we verify

HD PepGNP-Covid19

Gylden Pharma Ltd · Phase 1 active Biologic

HD PepGNP-Covid19 is a Biologic drug developed by Gylden Pharma Ltd. It is currently in Phase 1 development.

At a glance

Generic name	HD PepGNP-Covid19
Sponsor	Gylden Pharma Ltd
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HD PepGNP-Covid19 CI brief — competitive landscape report
HD PepGNP-Covid19 updates RSS · CI watch RSS
Gylden Pharma Ltd portfolio CI

Frequently asked questions about HD PepGNP-Covid19

What is HD PepGNP-Covid19?

HD PepGNP-Covid19 is a Biologic drug developed by Gylden Pharma Ltd.

Who makes HD PepGNP-Covid19?

HD PepGNP-Covid19 is developed by Gylden Pharma Ltd (see full Gylden Pharma Ltd pipeline at /company/gylden-pharma-ltd).

What development phase is HD PepGNP-Covid19 in?

HD PepGNP-Covid19 is in Phase 1.

Manufacturer: Gylden Pharma Ltd — full pipeline
Compare: HD PepGNP-Covid19 vs similar drugs
Pricing: HD PepGNP-Covid19 cost, discount & access